Barbara Wallner

Barbara Wallner

Company: Samus Therapeutics

Job title: CSO

Seminars:

Small molecule epichaperome inhibitors to treat cancers and neurodegenerative disease 8:10 am

Icapamespib (PU-AD) a small molecule epichaperome inhibitor is being developed for brain cancers and neurodegenerative diseases Icapamespib is BBB permeable, inhibits epichaperome activity, initiates degradation of disease associated proteins, normalizes cellular pathways and causes cancer cell death or recovery of neuronal functions In preclinical studies icapamespib decreased tumor growth in human GBM explant xenografts, initiated…Read more

day: Day Two

© Copyright 2022 Hanson Wade | Design and site by Event Engine | Hanson Wade Limited is registered in England & Wales, number 06752216.
Registered Office: Suite A, 6 Honduras Street, London EC1Y 0TH.